Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.

leflunomide
rheumatoid factor
golimumab
cyclic citrullinated peptide antibody
chloroquine
  • 0 views
  • 22 Apr, 2022
  • 9 locations
A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment.

  • 14 views
  • 25 Oct, 2022
  • 67 locations
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment. Phase 1 part: Around 20~40 patients will be subsequently …

systemic therapy
measurable disease
peripheral t-cell lymphoma
t-cell lymphoma
  • 6 views
  • 07 Oct, 2022
  • 44 locations
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (MARBLE-23)

This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis. It will consist of phase II and phase III parts, phase II will be a dose-ranging part and phase III will …

topical agents
  • 0 views
  • 07 Oct, 2022
  • 18 locations
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sj(SqrRoot)(Delta)Gren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies

Background An autoimmune disease is one in which the immune system attacks a person s own body. Sjogren's syndrome (SS) is an autoimmune disease. It often involves multiple systems and organs of the body. Researchers are trying to find new, more effective and safe treatments for SS. Objective To evaluate …

tofacitinib
chloroquine
glucocorticoids
autoimmune disease
hydroxychloroquine
  • 0 views
  • 22 Oct, 2022
  • 1 location
Advanced Therapeutics in Rheumatoid Arthritis (RA)

This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA

tofacitinib
leflunomide
tumor necrosis factor
methotrexate
hydroxychloroquine
  • 13 views
  • 24 May, 2022
  • 1 location
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

In this trial, the investigators will begin to explore the possibility that, as in mice, janus kinase inhibitor 1 (JAK1) inhibition with haploidentical-hematopoietic cell transplantation (HCT

leukapheresis
lymphoid leukemia
carbon monoxide
ejection fraction
cell transplantation
  • 0 views
  • 04 Oct, 2022
  • 1 location
Korean Post-marketing Surveillance for Xeljanz XR (Registered) (XRPMS)

Xeljanz(tofacitinib) is a potent, oral janus kinase inhibitor. Xeljanz Tab 5mg was approved by MFDS in 2014 for the treatment of adult patients with moderately to severely active rheumatoid

  • 0 views
  • 25 Oct, 2022
  • 1 location